2024
Comprehensive characterization of ERBB2 genomic alterations inlung cancer.
El Zarif T, Stockhammer P, Schillo J, Goldberg S, Politi K, Grant M. Comprehensive characterization of ERBB2 genomic alterations inlung cancer. Journal Of Clinical Oncology 2024, 42: 3148-3148. DOI: 10.1200/jco.2024.42.16_suppl.3148.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalShorter progression-free survivalTyrosine kinase domainSystemic therapyCo-mutationsClinical characteristics of non-small cell lung cancerCharacteristics of non-small cell lung cancerFirst-line platinum-based chemotherapyMedian tumor mutation burdenNon-small cell lung cancer tumorsFirst-line systemic therapyTP53 co-mutationsPlatinum-based chemotherapyTumor mutational burdenKaplan-Meier methodCell lung cancerLog-rank testOptimal treatment strategyHistory of smokingCopy number profilesTumor profile dataJuxtamembrane domainSquamous histologyTrastuzumab deruxtecan
2019
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
Rizvi N, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, van den Heuvel M, Dols M, Vicente D, Smolin A, Moiseyenko V, Antonia S, Nakagawa K, Goldberg S, Kim E, Walker J, Raja R, Liu F, Scheuring U, Peters S. Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. Journal Of Clinical Oncology 2019, 37: 9016-9016. DOI: 10.1200/jco.2019.37.15_suppl.9016.Peer-Reviewed Original ResearchBlood tumor mutational burdenPredictive biomarkersPD-L1Tumor cell PD-L1 expressionPD-L1 IHC assaysAppropriate predictive biomarkersFirst-line durvalumabPD-L1 TCTumor PD-L1PD-L1 expressionPlatinum-based chemotherapyTumor mutational burdenExploratory analysisMetastatic NSCLCTreatment decisionsMutational burdenChemotherapyIHC assaysTC expressionBiomarkersSmall sample sizeExpression levelsFurther investigationOSAdditional cutoffs